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Previewsa LTbR-dependent fashion. Moreover,
stimulated mVSMCs form a fibroblastic
reticular cell network-like structure that
is typical for SLOs (Gra¨bner et al., 2009).
However, the LTo cell function is not
confined to fibroblastic cells because
lymph node formation, for example, re-
quires LTbR signaling in vascular endo-
thelial cells (Onder et al., 2013). Hu et al.
(2015) solved not only the question con-
cerning the nature of the organizer cell
for ATLO formation, but also found an
elegant way around the confounding
factor that altered immune responsive-
ness in globally LTbR-deficient mice led
to accelerated atherosclerosis. In the
core dataset of this study, conditional
Ltbr gene ablation specifically in VSMC
has been achieved through SM22a pro-
moter-driven Cre recombinase expres-
sion. Thorough characterization of SLOs
of conditionally LTbR-deficient animals
on the apolipoprotein E-deficient back-
ground revealed the absence of general
immune system alterations. Importantly,
selective ablation of the LTbR revealed
that VSMCs limit atherosclerotic dis-
ease progression in aging apolipoprotein
E-deficient mice, while initial lesion devel-
opment was not affected. Hence, these
findings suggest that the senescent im-
mune system selectively employs the
LTbR on VSMCs to foster ATLO formationand thereby locally restrains the athero-
sclerotic process. However, it needs to
be clarified in future studies how T cell
education within ATLOs impinges on the
chronic atherosclerotic lesion develop-
ment. It is possible that ATLO-dependent
local induction of regulatory T cells fosters
generation of anti-inflammatory macro-
phages and antagonizes foam cell forma-
tion (Figure 1).
The findings of Hu et al. (2015) provide
not only novel insight into core processes
during atherogenesis, but also teach a
new lesson on the role of TLOs in the pro-
gression of local inflammation. In fact, it
has been a matter of debate whether
TLOs enforce or attenuate chronic inflam-
mation or autoimmune disease. One ma-
jor obstacle in resolving this issue has
been the genetic link between SLO devel-
opment and TLO formation. Hence,
uncoupling of TLO formation from SLO
development through VSMC-specific ge-
netic Ltbr-ablation clearly points toward
a novel and important immune regulatory
function of TLOs. Identification of specific
markers for LTo cells in TLOs of other
tissues would open new options for ge-
netic manipulation of these cells in vivo
and to revisit their role in chronic inflam-
matory reactions.
In sum, TLOs in the wall of atheroscle-
rotic arteries might guide us to new break-Immunitythroughs in getting control on chronic
inflammation.
REFERENCES
Gra¨bner, R., Lo¨tzer, K., Do¨pping, S., Hildner, M.,
Radke, D., Beer, M., Spanbroek, R., Lippert, B.,
Reardon, C.A., Getz, G.S., et al. (2009). J. Exp.
Med. 206, 233–248.
Hansson, G.K. (2005). N. Engl. J. Med. 352, 1685–
1695.
Hansson, G.K., and Hermansson, A. (2011). Nat.
Immunol. 12, 204–212.
Hu, D., Mohanta, S.K., Yin, C., Peng, L., Ma, Z., Sri-
kakulapu, P., Grassia, G., MacRitchie, N., Dever,
G., Gordon, P., et al. (2015). Immunity 42, this
issue, 1100–1115.
Junt, T., Scandella, E., and Ludewig, B. (2008). Nat.
Rev. Immunol. 8, 764–775.
Lo¨tzer, K., Do¨pping, S., Connert, S., Gra¨bner, R.,
Spanbroek, R., Lemser, B., Beer, M., Hildner, M.,
Hehlgans, T., van der Wall, M., et al. (2010). Arte-
rioscler. Thromb. Vasc. Biol. 30, 395–402.
Onder, L., Danuser, R., Scandella, E., Firner, S.,
Chai, Q., Hehlgans, T., Stein, J.V., and Ludewig,
B. (2013). J. Exp. Med. 210, 465–473.
van de Pavert, S.A., and Mebius, R.E. (2010). Nat.
Rev. Immunol. 10, 664–674.
Watanabe, M., Sangawa, A., Sasaki, Y., Yama-
shita, M., Tanaka-Shintani, M., Shintaku, M., and
Ishikawa, Y. (2007). J. Atheroscler. Thromb. 14,
325–331.
Wick, G., Romen, M., Amberger, A., Metzler, B.,
Mayr, M., Falkensammer, G., and Xu, Q. (1997).
FASEB J. 11, 1199–1207.DC-SIGN: The Strange Case
of Dr. Jekyll and Mr. HydeJuan J. Garcia-Vallejo1,* and Yvette van Kooyk1,*
1Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam MF-B242, 1081BT, the Netherlands
*Correspondence: jj.garciavallejo@vumc.nl (J.J.G.-V.), y.vankooyk@vumc.nl (Y.v.K.)
http://dx.doi.org/10.1016/j.immuni.2015.05.021
In this issue of Immunity, Conde et al. (2015) showed that a costimulatory blockade favors the accumulation
of CD209a+ macrophages which, upon interaction with fucosylated tissue ligands, promotes the expansion
of CD4+Foxp3+ Treg cell number.The control of peripheral tolerance to self-
antigens is one of the mechanisms that
define immune homeostasis. An effective
peripheral tolerance ensures that autor-
eactive T cells that have escaped nega-tive selection during thymic education
are kept under control to avoid autoimmu-
nity. In addition, excess of tolerance is
avoided to allow the immune system to
respond with proper capacity againstpathogens. Dysregulation of this fine
equilibrium leads to important repercus-
sions on both sides of the balance: the
development of autoimmunity when toler-
ance is poor and the facilitation of tumor42, June 16, 2015 ª2015 Elsevier Inc. 983
Immunity
Previewsimmune escape when tolerance is exces-
sive. The central elements in the control
of peripheral tolerance are the suppressor
T cells, generically referred toas regulatory
T (Treg) cells, which use different inhibitory
modules to achieve their inhibitory func-
tion. Now classical experiments have
demonstrated that although mice
depleted of Treg cells spontaneously
develop autoimmunity and chronic in-
flammation, they are better prepared to
reject incipient tumors. In contrast, in vivo
enrichment with Treg cells allows mice
to accept allogeneic transplantations
(Sakaguchi et al., 2008). Thus, Treg cells
have emerged as a component of the im-
mune system with tremendous potential
in the treatment of autoimmunity and
cancer and in transplantation medicine.
Still, our understanding of the endogenous
mechanisms regulating thegenerationand
maintenance of Treg cells remains poor.
Several antigen-presenting cell types
have been associated with the differentia-
tion of naive T cells into Treg cells, mostly
in the context of immaturity or partial
maturation. In this setting, co-inhibitory
molecules and suppressing cytokines,
such as transforming growth factor b
(TGF-b) and interleukin-10 (IL-10), provide
negative signaling to the T cells that pro-
motes anergy and immunosuppression.
Among the antigen-presenting cells able
to trigger the differentiation of Treg cells
are tumor-infiltrating myeloid-derived
suppressor cells and macrophages and
dendritic cells (DCs) that are subverted
by pathogens to produce IL-10 (Walsh
and Mills, 2013). In both tumor-infiltrating
myeloid-derived suppressor cells and
pathogen-modulated DCs and macro-
phages, the microenvironment plays a
critical role in determining the tolerogenic
transcriptional profile that triggers the
expression of inhibitory co-stimulatory
molecules and the key cytokine IL-10.
Tolerogenic profiles in antigen-presenting
cells are instructed through the pattern-
recognition receptor DC-SIGN that
senses the microenvironment (Garcı´a-
Vallejo and van Kooyk, 2013).
In humans, CD209, also known as DC-
SIGN (DC-specific intercellular adhesion
molecule-3 grabbing non-integrin), has
long been considered a DC marker
because of its expression on immature
DCs in peripheral tissue and mature DCs
in lymphoid tissues, although not on follic-
ular DCs, plasmacytoid DCs, or CD1a+984 Immunity 42, June 16, 2015 ª2015 ElsevLangerhans cells (Geijtenbeek et al.,
2000). However, CD209 has also been
described on different types of macro-
phage-like subpopulations, such as
microglia, tumor-infiltrating ‘‘M2’’ macro-
phages, myeloid-derived suppressor
cells, andCD14+ dermal, decidual, and in-
testinal macrophages. As a type 2 C-type
lectin receptor, CD209 is equipped with a
carbohydrate recognition domain (CRD)
that mediates the recognition of fucose
(Lea, Leb, LeX, LeY, and sulfo-Lea) and
high-mannose glycans in a Ca2+-depen-
dent manner (Feinberg et al., 2001).
These carbohydrate structures can be
found in multiple pathogens (e.g., HIV,
Dengue virus, Lassa virus, Ebola virus,
M. tuberculosis, C. albicans, S. mansoni,
and H. pylori, among others), but also on
human glycoproteins, such as ICAM-2,
ICAM-3, Mac-1, carcinoembriogenic anti-
gen, butyrophilin, milk bile-salt stimulated
lipase, myelin-oligodendrocyte glycopro-
tein, and semen clusterin (Garcı´a-Vallejo
and van Kooyk, 2013). Most importantly,
interaction of DC-SIGN with some of its
endogenous and pathogenic ligands,
and in the context of simultaneous trig-
gering of Toll-like receptor 4 (TLR4), has
been shown to elicit a synergistic increase
in the expression and secretion of IL-10,
setting on anti-inflammatory circuits char-
acterized by decreased T cell proliferation
and the generation of anergic or Treg
cells. Now, Conde et al. report in this issue
of Immunity (Conde et al., 2015) that one
of the eight genetic paralogs of DC-
SIGN in mice, CD209a (also reported in
literature as SIGNR5, gene ID: 170786) is
expressed on a CSF1-induced subset of
suppressive macrophages characterized
as CD11b+CSF1R+Ly6CloLy6GCD169+
cells. These cells are generated in
allogeneic grafts from CD11b+CSF1R+
Ly6ChiLy6GCD169 cells by the action
of allograft-produced CSF1. CD209a
on CD11b+CSF1R+Ly6CloLy6GCD169+
cells engages with fucosylated glycans
in the allogeneic graft and, in the context
of TLR4 signaling, trigger the expression
and secretion of IL-10 (Figure 1) which,
in turns, mediates the differentiation of
Treg cells that are crucial for the
survival of the graft (Conde et al., 2015).
Elegant experiments using organs from
FucT-IV and FucT-VII double-deficient
mice demonstrate that the absence of
a1,3-fucosylated glycans in the alloge-
neic graft prevents the triggering ofier Inc.CD209a-dependent IL-10 production. As
expected, Cd209a/ mice failed to
accept the graft due to the lack of the
necessary IL-10 to build the peripheral
tolerance against the allogeneic heart.
The mouse model reported by Conde
et al. (2015) closely resembles the findings
observed in vitro on human CD209
(Figure 1) and suggests that the mouse
CD209a might be the most approximate
functional homolog of human CD209
(Garcı´a-Vallejo and van Kooyk, 2013).
Yet, several structural differences of
mouse CD209a versus human CD209
might posit a warning with regards
to this assumption, because mouse
CD209a has a considerably lower affinity
for the ligand, slightly different specificity,
and a shorter stem region, and is unable
to internalize (Garcı´a-Vallejo and van
Kooyk, 2013). In addition, the contribution
of other fucose-specific C-type lectins,
such as mouse MGL-1 (CD301a), which
has also been described to trigger macro-
phage-dependent anti-inflammatory cir-
cuits in an IL-10-dependent fashion, is
worth exploring. Yet, the protective role
of the IL-10-producing CD11b+CSF1R+
Ly6CloLy6GCD169+ cells in preventing
allograft rejection is indisputable and
paves the way to new therapeutic
avenues in transplantation. Interestingly,
DC-SIGN+ cells have been described
to infiltrate acute rejecting kidney human
allografts, correlating with poor prognosis
(Zuidwijk et al., 2012). Although thepheno-
type of the DC-SIGN+ cells in this report
was certainly more pro-inflammatory, it
would be extremely interesting to investi-
gate whether tissue-specific differences
in glycosylation might explain a lack of
DC-SIGN ligands in the kidney that could
aggravate the deficit of peripheral toler-
ance to the transplanted organ.
CD209a is not a specific marker of
tolerogenicmacrophagesas it couldbe in-
terpreted from the report of Conde et al.
(2015). Previous research has demon-
strated the presence of CD209a in a sub-
population of DCs arising frommonocytes
in vivo under the influence of TLR4
signaling (Figure 1). Such DCs lacked the
expression of monocyte markers, but
have high expression of TLR4 and CD14,
acquired the probing morphology of
DCs, localized to the T cell areas, and
showed powerful antigen-capturing, as
well as a highly effective capacity to pre-
sent antigens in MHC-I and -II (Cheong
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Figure 1. The Multifaceted Function of DC-SIGN
The interaction of CD209a on CD11b+CSF1R+Ly6CloLy6GCD169+ with fucosylated glycans on graft gly-
coproteins together with TLR4 triggering leads to the activation of a tolerogenic phenotype dominated by
IL-10 secretion. The human equivalent could be represented by microglia or myeloid-derived suppressor
cells. CD209 expressed on microglia interacts with fucosylated glycans on myelin oligodendrocyte glyco-
protein resulting in a synergistic upregulation of the TLR4-dependent IL-10 production. In contrast, tumors
that overexpress fucosylated structures interact with CD209 on myeloid-derived suppressor cells, pre-
sumably to enhance their tolerogenic function. However, CD209 is not only a signaling receptor, and it
has been clearly demonstrated that glycan-conjugated antigens targeted to CD209 are efficiently pre-
sented in MHC-I and MHC-II to induce CD8+ and CD4+ effector T cells, respectively. Thus, expression
of CD209 on CD14+ and some subpopulations of CD1a+ dermal DCs or CD11c+ conventional DCs provide
these cells with an antigen-dependent immunogenic pathway. The mice equivalent could be a subset of
DCs that result from the exposure of monocytes to LPS from gram bacteria. This triggers a transcriptional
profile that differentiates these cells into CD14+CD209a+ highly immunogenic DCs with CD4+ and CD8+
T cell activation capacity.
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Previewset al., 2010). Unfortunately, experiments
aimed at investigating the function of
CD209a on in vivo monocyte-derived
DCs were not pursued in this manuscript
and have not yet been reported. Evidence
so far points in the direction of CD209a
resembling the dual role reported for hu-
man CD209 in mediating both tolerance
and immunity, depending on the context
of CD209 triggering. Thus, the natural
function of human CD209 would be the
maintenanceof immunological homeosta-
sis through the interaction with multiplehost glycoproteins in order to keepperiph-
eral tolerance, while providing a pathway
for antigen processing and presentation.
The tolerogenic aspect of human CD209
might have been hijacked by pathogens
and tumors, which have learned to upre-
gulate the expression of CD209-ligands
in order to take advantage of CD209-
dependent tolerogenic signaling circuits
as a strategy to escape the immune sys-
tem. But at the same time, human CD209
is an extremely efficient internalization re-
ceptor that mediates routing to intracel-Immunitylular compartments involved in MHC-I
and -II antigen presentation (Figure 1).
The strategic localization of CD209 in
both dermalDCs, aswell as in paracortical
DCs in the lymph nodes, and its sensitivity
to be upregulated by growth factors, such
as GM-CSF, ensures that, together with a
proper adjuvant, antigens targeted to hu-
man CD209 are effectively presented to
T cells and result in the generation of
strong immune responses (Tacken et al.,
2005; Unger et al., 2012), thus a definitely
interestingoption in vaccinedevelopment.
As the main character in Stevenson’s
famednovelTheStrangeCaseofDr. Jekyll
and Mr. Hyde, CD209 represents the alle-
gory of good and evil contained within the
same identity. It could be that the molecu-
lar context of the type of myeloid-derived
antigen-presenting cell that expresses
CD209 and the glycosylation microenvi-
ronment determines the balance between
toleranceand immunity uponCD209 inter-
action. And in doing so, CD209 provides
us with a sensitive and sophisticated way
of manipulating the immune system in
the desired direction.REFERENCES
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